BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36879662)

  • 1. Discovery of novel thyrointegrin αvβ3 antagonist fb-PMT (NP751) in the management of human glioblastoma multiforme.
    Godugu K; Hay BA; Glinsky GV; Mousa SA
    Neurooncol Adv; 2023; 5(1):vdac180. PubMed ID: 36879662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Thyrointegrin αvβ3 Using Fluorobenzyl Polyethylene Glycol Conjugated Tetraiodothyroacetic Acid (NP751) in Acute Myeloid Leukemia.
    Darwish NHE; Glinsky GV; Sudha T; Mousa SA
    Front Oncol; 2021; 11():793810. PubMed ID: 35155195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of fluorobenzyl polyethylene glycol conjugated tetraiodothyroacetic acid (NP751), a novel anticancer thyrointegrin α
    Fujioka K; Hay BA; Godugu K; Mousa SA
    Front Pharmacol; 2022; 13():902141. PubMed ID: 36518666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin α
    Rajabi M; Godugu K; Sudha T; Bharali DJ; Mousa SA
    Bioconjug Chem; 2019 Dec; 30(12):3087-3097. PubMed ID: 31714064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Cancer Activities of Thyrointegrin α
    Godugu K; Rajabi M; Mousa SA
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Thyrointegrin α
    Hay BA; Godugu K; Darwish NHE; Fujioka K; Sudha T; Karakus OO; Mousa SA
    J Med Chem; 2021 May; 64(9):6300-6309. PubMed ID: 33886292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of dual targeting PEGylated BG-P
    Ozen Karakus O; Godugu K; Mousa SA
    Bioorg Med Chem; 2021 Aug; 43():116278. PubMed ID: 34157571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin α
    Sudha T; Godugu K; Glinsky GV; Mousa SA
    Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Polyethylene Glycol-Conjugated Triazole Derivative with High Thyrointegrin αvβ3 Affinity in Acute Myeloid Leukemia Management.
    Sudha T; Godugu K; Darwish NHE; Nazeer T; Mousa SA
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction to "Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin α
    Rajabi M; Godugu K; Sudha T; Bharali DJ; Mousa SA
    Bioconjug Chem; 2023 Feb; 34(2):453. PubMed ID: 36709499
    [No Abstract]   [Full Text] [Related]  

  • 11. Correction to "Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin α
    Rajabi M; Godugu K; Sudha T; Bharali DJ; Mousa SA
    Bioconjug Chem; 2021 Apr; 32(4):859. PubMed ID: 33689298
    [No Abstract]   [Full Text] [Related]  

  • 12. Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin αvβ3 Receptors in the Treatment of Neuroblastoma.
    Karakus OO; Godugu K; Rajabi M; Mousa SA
    J Med Chem; 2020 Jul; 63(14):7653-7662. PubMed ID: 32571015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer Efficacy and Mechanisms of a Dual Targeting of Norepinephrine Transporter and Thyrointegrin αvβ3 Antagonist in Neuroblastoma.
    Godugu K; Karakus OO; Fujioka K; Glinsky GV; Mousa SA
    J Cancer; 2022; 13(8):2594-2606. PubMed ID: 35711848
    [No Abstract]   [Full Text] [Related]  

  • 14. RETRACTED: Godugu et al. Anti-Cancer Activities of Thyrointegrin α
    Godugu K; Rajabi M; Mousa SA
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano-Targeting of Thyrointegrin αvβ3 Receptor in Solid Tumors and Impact on Radiosensitization.
    Sudha T; Rehman MU; Darwish NHE; Coskun MD; Satti JA; Davis PJ; Mousa SA
    Radiat Res; 2021 Oct; 196(4):375-385. PubMed ID: 34260732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Anticancer Agent P-bi-TAT on Gene Expression Link the Integrin Thyroid Hormone Receptor to Expression of Stemness and Energy Metabolism Genes in Cancer Cells.
    Glinsky GV; Godugu K; Sudha T; Rajabi M; Chittur SV; Hercbergs AA; Mousa SA; Davis PJ
    Metabolites; 2022 Apr; 12(4):. PubMed ID: 35448512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction: Godugu et al. Anti-Cancer Activities of Thyrointegrin α
    Godugu K; Rajabi M; Mousa SA
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
    Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
    J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.
    Mancini A; Colapietro A; Cristiano L; Rossetti A; Mattei V; Gravina GL; Perez-Montoyo H; Yeste-Velasco M; Alfon J; Domenech C; Festuccia C
    Front Oncol; 2022; 12():943064. PubMed ID: 36408162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.